Valladares-Ayerbes, Manuel http://orcid.org/0000-0002-7950-9584
Safont, Maria José
González Flores, Encarnación
García-Alfonso, Pilar
Aranda, Enrique
Muñoz, Ana-Maria López
Falcó Ferrer, Esther
Cirera Nogueras, Luís
Rodríguez-Salas, Nuria
Aparicio, Jorge
Llanos Muñoz, Marta
Pimentel Cáceres, Paola Patricia
Castillo Trujillo, Oscar Alfredo
Vidal Tocino, Rosario
Salgado Fernández, Mercedes
Salud-Salvia, Antonieta
Massuti Sureda, Bartomeu
Garcia-Carbonero, Rocio
Vicente Conesa, Maria Ángeles
Lloansí Vila, Ariadna
,
Funding for this research was provided by:
This study was funded by AMGEN S.A.
Article History
Received: 1 March 2024
Accepted: 25 March 2024
First Online: 20 April 2024
Declarations
:
: Manuel Valladares-Ayerbes has received grants and personal fees from Roche, and personal fees from Merck, Amgen, Sanofi, Servier, Celgene and Bayer. María José Safont has received personal fees from Roche, Amgen, Merck and Sanofi, and honoraria for speaker/consulting roles from Amgen, Bayer, BMS, Merck, MSD, Pierre Fabre, Roche, Sanofi and Servier. Encarnación González Flores has received honoraria for advisory board member and speaker from Amgen y Merck. Pilar García-Alfonso has received honoraria or consultation fees for speaker, consultancy or advisory roles from Amgen, Bayer, Bristol, Merck Seorono, MSD, Lilly, Roche, Sanofi, Servier and Pierre Fabre. Rosario Vidal Tocino has received speaker fees from Amgen, Merck, Sanofi, Servier, Bristol-MS, Bayer and Roche and educational and scientific activities and travel support from Amgen, Roche, Lilly, Sanofi, Bristol-MS, Pierre-Fabre and Servier. Enrique Aranda has received honoraria for advisory role from Amgen, Bayer, Bristol Myers Squibb, Merck, Roche, Sanofi, Servier. Research funding from Roche. Ana-Maria Lopez Muñoz has received honoraria for a consultant or advisory role from Amgen, Bayer, Roche and for speaking from Eisai, Lilly, Amgen, Bayer, Sanofi, Merck Serono, Roche, Bristol, Servier, Pierre Fabre. Nuria Rodriguez-Salas has received honoraria for the advisory role from Bayer, Roche and Amgen and for a speaker from Bayer, Roche, Amgen, MSD and Servier. Jorge Aparicio has received honoraria for consultant or advisory roles from Amgen, Merck, Sanofi, Servier, Bayer and Pierre Fabre. Mercedes Salgado Fernández has received honoraria for speaking and advisory roles for Amgen, AstraZeneca, Eisai, MSD, Roche, Merck Serono, Servier, Lilly, Sanofi, Rovi, Leo-Pharma, Techdow. Bartomeu Massuti Sureda has received honoraria for speaking and/or advisory roles for Astra Zeneca, BMS, Boehringer Ingelheim, MSD, Roche, and BMS. He has been the principal investigator/affiliate/member and/or has had a leadership role in Astra Zeneca, MSD, ASCO, IASLC, SEOM and SLCG. Rocio Garcia-Carbonero has received honoraria for speaker/consulting roles from Advanz Pharma, Bayer, BMS, Boehringer, Hutchmed, Ipsen, Merck, Midatech Pharma, MSD, Novartis, PharmaMar, Pfizer, Pierre Fabre, Roche, Sanofi and Servier, and research support from Pfizer, BMS and MSD. Ariadna Lloansí Vila is an employee and stakeholder of Amgen S.A. The other authors declare no potential conflicts of interest.
: The protocol was approved by an independent ethics committee <i>CEIC Consorcio Hospitalario Provincial de Castellón</i> (Spain), and all patients gave their written informed consent before enrollment.
: Not applicable.